ADMA Biologics (ADMA) Competitors

ADMA Biologics (NASDAQ:ADMA) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Does the media favor ADMA or ACAD?

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.31 beat ACADIA Pharmaceuticals' score of 0.81 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders have more ownership in ADMA or ACAD?

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts prefer ADMA or ACAD?

ADMA Biologics currently has a consensus target price of $27.67, suggesting a potential upside of 56.26%. ACADIA Pharmaceuticals has a consensus target price of $27.88, suggesting a potential upside of 23.56%. Given ADMA Biologics' stronger consensus rating and higher possible upside, research analysts clearly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
ACADIA Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71

Which has stronger earnings & valuation, ADMA or ACAD?

ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$426.45M	9.91	$197.67M	$0.85	20.83
ACADIA Pharmaceuticals	$996.28M	3.79	$226.45M	$1.37	16.47

Which has more volatility & risk, ADMA or ACAD?

ADMA Biologics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Is ADMA or ACAD more profitable?

ADMA Biologics has a net margin of 45.01% compared to ACADIA Pharmaceuticals' net margin of 22.97%. ADMA Biologics' return on equity of 47.16% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	45.01%	47.16%	30.51%
ACADIA Pharmaceuticals	22.97%	17.46%	10.75%

Summary

ADMA Biologics and ACADIA Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.